JAK2 and non-small cell lung carcinoma: Studies have shown that dysregulated IL-6 or JAK2 can reprogram the STAT3 pathway in metastatic tumor cells, induce recruitment of myeloid-derived suppressor cells (MDSCs) and polarized macrophages, and repress the infiltration of CD8+ T cells to evade host immunity in NSCLC [24,25,26].